The latest market price and reference cost of Guselkumab in 2026

Guselkumab (Guselkumab) is a monoclonal antibody targeting IL-23 and is mainly used to treat patients with moderate to severe plaque psoriasis. It reduces the production of inflammatory mediators by inhibiting the IL-23 signaling pathway, thereby reducing skin inflammation and scaly formation, and improving patient symptoms and quality of life. The drug is clinically administered as a subcutaneous injection, usually by a professional medical institution or trained medical staff.

In the domestic market, guselkumab has been officially launched for sale, with a price of about four to five thousand yuan per box. The specific price may vary depending on regional pharmacies and supply conditions. When purchasing, patients should refer to the actual price of the local regular hospital or pharmacy and follow the doctor's prescription. Medications are usually formatted and packaged as single injection doses, making it easy for patients to follow the recommended course of treatment.

Guselkumab has been included in domestic medical insurance, and patients who meet the conditions can receive a certain percentage of reimbursement according to local medical insurance policies. Due to differences in medical insurance policies in various places, the reimbursement ratio and reimbursement process may be different. Patients should consult the hospital or medical insurance department for specific reimbursement details before use in order to reasonably arrange financial expenditures and reduce the burden of treatment.

In addition, to ensure the safety of medication, patients should follow the doctor's instructions for subcutaneous injection while using guselkumab, and pay attention to the injection site reaction and systemic adverse reactions, such as mild redness, swelling, itching or signs of infection. Regular follow-up, evaluation of skin symptom improvement, and monitoring of laboratory indicators will help determine efficacy and adjust medication regimen. Overall, guselkumab has been launched and covered by medical insurance in China, providing a safe and standardized treatment option for psoriasis patients.

Reference materials:https://pubmed.ncbi.nlm.nih.gov/30042659/